No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.7x · 10Y median 4.3x · 42nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2023-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2025-11-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2025-11-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2023-05-09.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2023-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2025-11-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:08.705Z. Latest historical point 2025-11-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cytek Biosciences, Inc. (CTKB) stock was $5.98 as of Oct 6, 2026, 10:00 AM EDT, down 1.81% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +53.1% · 3-year avg +3.8%/yr · 5-year avg -23.2%/yr
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings.
Medical - Devices · Fremont, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.07
Revenue Est.
$52.95M
Last Quarter Results
EPS
$-0.03
vs Estimate
$-0.02
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CTKB | $772.27M | $5.98 | -1.81% | +53.09% | -23.16% | N/A | N/A |
| 2LXRX | $771.12M | $1.74 | -0.23% | +23.28% | -18.54% | -21.03% | vs CTKB |
| 3GERN | $769.83M | $1.20 | -0.83% | -10.32% | -1.87% | -6.18% | vs CTKB |
| 4ATTO | $777.55M | $18.07 | +0.42% | N/A | N/A | N/A | vs CTKB |
| 5DSGN | $759.16M | $12.15 | -2.13% | +102.59% | -3.82% | N/A | vs CTKB |
| 6MLAB | $789.47M | $141.08 | -0.81% | +94.75% | -13.52% | +2.29% | vs CTKB |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$48.14M
vs Estimate
$47.31M
Consensus Rating
Based on 4 analysts
Average Price Target
$5.56
-7.0% downside
Low
$4.75
Current
$5.98
High
$7.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Dec 2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Quarter ending Mar 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Quarter ending Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.35 | $-0.34 | $-0.34 | 1 |
| FY 2027 | $-0.26 | $-0.25 | $-0.25 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $52.44M | $52.95M | $53.45M | 2 |
| Quarter ending Dec 2026 | $63.57M | $63.65M | $63.72M | 2 |
| Quarter ending Mar 2027 | $48.16M | $48.40M | $48.57M | 1 |
| Quarter ending Jun 2027 | $51.59M | $51.85M | $52.04M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $208.85M | $209.43M | $210.00M | 3 |
| FY 2027 | $223.22M | $223.24M | $223.25M | 3 |
